Content about Headaches

January 3, 2013
Par ships migraine drug

Par Pharmaceutical Cos. has started shipping two formulations of a generic drug for treating migraines, the company said.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has started shipping two formulations of a generic drug for treating migraines, the company said.

Par announced the shipment of rizatriptan benzoate tablets and rizatriptan benzoate orally disintegrating tablets in the 5-mg and 10-mg strengths. The drug is used to treat acute migraine with or without aura in patients ages 6 years and older.

The drug has sales of about $653 million per year, according to IMS Health.

November 27, 2012
Akeso Health launches supplement addressing nutritional deficiencies common to migraine sufferers

Akeso Health Sciences on Tuesday announced the availability of MigreLief Triple Therapy with Puracol, a nonprescription, comprehensive supplement formulated to maintain normal cerebrovascular function by addressing the underlying nutritional deficiencies and imbalances common to many migraine sufferers.

LOS ANGELES — Akeso Health Sciences on Tuesday announced the availability of MigreLief Triple Therapy with Puracol, a nonprescription, comprehensive supplement formulated to maintain normal cerebrovascular function by addressing the underlying nutritional deficiencies and imbalances common to many migraine sufferers.   

November 14, 2012
Novartis Consumer launches My Migraine Triggers app

Novartis Consumer Health on Wednesday announced the development of a convenient migraine trigger tracking tool, My Migraine Triggers App, with a neurologist.

PARSIPPANY, N.J. — Novartis Consumer Health on Wednesday announced the development of a convenient migraine trigger tracking tool, My Migraine Triggers App, with a neurologist. The company also partnered with Jordin Sparks, singer, actress and Broadway performer, and Keri Peterson, an internist at Lenox Hill Hospital, on the launch of "Managing Migraines: Know Your Triggers. Know Your Treatment," an educational campaign to raise awareness around the importance of knowing individual migraine triggers. 

September 4, 2012
Bayer HealthCare brings OTC migraine relief to analgesic shelves

Bayer HealthCare's Consumer Care Division on Tuesday introduced Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms like nausea, phonophobia (sound sensitivity) and photophobia (light sensitivity) through a formulation of aspirin, acetaminophen and caffeine.

MORRISTOWN, N.J. — Bayer HealthCare's Consumer Care Division on Tuesday introduced Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms like nausea, phonophobia (sound sensitivity) and photophobia (light sensitivity) through a formulation of aspirin, acetaminophen and caffeine.

February 1, 2012
Impax licenses migraine drug rights from AstraZeneca

Impax Pharmaceuticals said Wednesday that it obtained exclusive U.S. commercial rights to a drug for migraine headaches made by AstraZeneca.

HAYWARD, Calif. — Impax Pharmaceuticals said Wednesday that it obtained exclusive U.S. commercial rights to a drug for migraine headaches made by AstraZeneca.

January 25, 2012
NARB upholds Advil's challenge of Excedrin's faster-relief claims

The National Advertising Review Board on Tuesday recommended that Novartis Consumer Health discontinue advertising claims that the company’s Excedrin Extra Strength product starts relieving headache pain faster than Advil.

NEW YORK — The National Advertising Review Board on Tuesday recommended that Novartis Consumer Health discontinue advertising claims that the company’s Excedrin Extra Strength product starts relieving headache pain faster than Advil.

The claims at issue were initially challenged before the National Advertising Division of the Council of Better Business Bureaus by Pfizer Consumer Healthcare, makers of Advil.

July 12, 2011
Nonprescription migraine med study to be presented at Headache Update Conference

PuraMed BioScience on Monday announced that headache researcher Roger Cady will be exhibiting a poster presentation of his independent clinical study of PuraMed's nonprescription migraine medication LipiGesic-M at the 2011 Headache Update Conference being held in Orlando, Fla., July 14 to 17.

SCHOFIELD, Wis. — PuraMed BioScience on Monday announced that headache researcher Roger Cady will be exhibiting a poster presentation of his independent clinical study of PuraMed's nonprescription migraine medication LipiGesic-M at the 2011 Headache Update Conference being held in Orlando, Fla., July 14 to 17.

February 3, 2011
US WorldMeds introduces Alsuma

US WorldMeds has announced a new treatment for migraines, the drug maker said Wednesday.

LOUISVILLE, Ky. — US WorldMeds has announced a new treatment for migraines, the drug maker said Wednesday.

The company announced the launch of Alsuma auto-injector (sumatriptan), which injects the drug sumatriptan under the skin via a single-use, prefilled auto injector. The company is selling the drug under a licensing agreement from King Pharmaceuticals.

October 17, 2010
Botox approved for migraines

A popular beauty treatment has won approval as a medical treatment as well....

SILVER SPRING, Md. A popular beauty treatment has won approval as a medical treatment as well.

 

The Food and Drug Administration announced Friday the approval of Allergan’s Botox (onabotulinumtoxinA) for preventing headaches in adult patients with chronic migraine.

 

 

August 1, 2010
Sagent's generic Imitrex receives regulatory approval

The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals...

SCHAUMBURG, Ill. The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals for treating migraine attacks, Sagent said Monday.

 

The FDA approved Sagent’s sumatriptan succinate injection in the 6 mg per 0.5 milliliter strength. The drug is used to treat acute migraine attacks and cluster headache episodes.

 

 

Sumatriptan is a generic version of GlaxoSmithKline’s Imitrex. Injectable sumatriptan had $22 million in sales in 2009, according to IMS Health.

July 11, 2010
Sandoz launches generic Amerge

Sandoz has launched a generic drug for treating migraine headaches, the generics arm of Swiss...

PRINCETON, N.J. Sandoz has launched a generic drug for treating migraine headaches, the generics arm of Swiss drug maker Novartis said Monday.

 

Sandoz launched naratriptan hydrochloride tablets in the 2.5-mg strength, a generic version of GlaxoSmithKline’s Amerge. The tablets are used for treating acute migraine attacks in adults with or without visual disturbances that occur before the onset of the headache, also known as aura. Studies have indicated that around 12% of Americans have migraine attacks.

 

 

June 7, 2010
Nautilus launches Cambia

Nautilus Neurosciences has launched a new treatment for migraines, the drug maker said Tuesday....

March 30, 2010
Cobroxin to be featured on morning talk show

XenaCare announced Wednesday that its over-the-counter pain reliever, Cobroxin, will be featured on a segment...

March 9, 2010
Decision Resources: Acute migraine therapy designed for vascular disease patients will capture market share

A company that develops a drug for acute migraines in pill form that doesn’t interact...

January 21, 2010
Carex relaunches headache band

Carex Health Brands on Friday relaunched the Thera-Med headache band, the company announced....